These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30659026)

  • 1.
    Mandilaras V; Garg S; Cabanero M; Tan Q; Pastrello C; Burnier J; Karakasis K; Wang L; Dhani NC; Butler MO; Bedard PL; Siu LL; Clarke B; Shaw PA; Stockley T; Jurisica I; Oza AM; Lheureux S
    Int J Gynecol Cancer; 2019 Feb; 29(2):346-352. PubMed ID: 30659026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Somatic
    Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized p53 immunohistochemistry is an accurate predictor of
    Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
    J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
    [No Abstract]   [Full Text] [Related]  

  • 6. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
    Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
    Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer.
    Park YR; Kim YM; Lee SW; Lee HY; Lee GE; Lee JE; Kim YT
    Obstet Gynecol Sci; 2018 May; 61(3):328-336. PubMed ID: 29780774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
    Kim HN; Woo HY; DO SI; Kim HS
    In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
    Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
    BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
    Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
    BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
    Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA
    Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
    Abdel-Fattah R; Challen C; Griffiths TR; Robinson MC; Neal DE; Lunec J
    Br J Cancer; 1998 Jun; 77(12):2230-8. PubMed ID: 9649138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncomorphic
    Brachova P; Mueting SR; Devor EJ; Leslie KK
    J Cancer Ther; 2014 Jun; 5(6):506-516. PubMed ID: 25339994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of somatic
    Yokouchi H; Nishihara H; Harada T; Yamazaki S; Kikuchi H; Oizumi S; Uramoto H; Tanaka F; Harada M; Akie K; Sugaya F; Fujita Y; Takamura K; Kojima T; Higuchi M; Honjo O; Minami Y; Watanabe N; Nishimura M; Suzuki H; Dosaka-Akita H; Isobe H
    Heliyon; 2020 Jul; 6(7):e04439. PubMed ID: 32685741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.